The eradication treatments of Helicobacter pylori by Wermeille, Joël et al.
R
e
v
ie
w
Introduction
Since its discovery in 1982 by Marshall and Warren
[1], the small curved bacterium successively named
Campylobacter pyloridis, then Campylobacter pylori
and finally Helicobacter pylori, has given rise to an
abundance of literature (150 publications in 1988,
1000 in 1990, several thousand at present), and the
number of works establishing a correlation between
this bacterium and different gastric and duodenal ail-
ments has not stopped growing.
But despite the explosion of fundamental and clini-
cal research in the area of H. pylori, tending to present
the gastric and duodenal ulcer for consideration as an
infectious disease, numerous questions remain con-
cerning the clinical importance of this bacterium and
the indications of the treatments for its elimination.
Whilst it is true that a close association exists
between peptic ulcers and infection by H. pylori (95%
of patients with a duodenal ulcer and 80% of patients
with a gastric ulcer are infected by this microorgan-
ism), there remains a very large prevalence of gastric
infestation by the bacterium in subjects with no histo-
ry of an ulcer (33% in the adult European population,
50% in the population of those over 50 years old in
developed countries, 70-90% in the adult population
in developing countries) [2-7]. It remains equally diffi-
cult to explain the extreme rarity of conjugal ulcers,
as 68% of the wives of male subjects who are H. pylori
positive are themselves infected by the bacterium [8].
The principal benefit expected from eradication of H.
pylori is the spectacular decrease in ulcer recurrence,
dropping from about 70% to less than 10% in the fol-
lowing year [7 9-11]. This is certainly a major benefit
but other treatment modalities can achieve similar
results. Selective vagotomy and chronic antisecretory
treatment (H2-receptor antagonist or proton pump
inhibitors) are also accompanied by a low rate of
relapse (about 2% per year for the former and 10-
30% for the latter) [10 12 13]. The eradication of H.
pylori is however the most cost effective treatment if
one considers that a patient can ‘recover’ from his
peptic ulcer disease in 7 to 14 days with adequate
antibiotic treatment, rather than undergo surgery or
several years of anti-secretory treatment [10 20 21].
Though H. pylori infection represents only one factor
of aggression among others (hydrochloric acid, pro-
teolytic enzymes, bile salts, NSAIDs, etc.), in ulcer dis-
ease it continues to be a key element, as its elimina-
tion alone serves to accelerate the healing of peptic
ulcer and considerably reduces the risk of recurrences,
including that of complicated ulcers, notably hemor-
rhagic [10 11 16-22].
At present, for a very large majority of specialists,
the eradication of H. pylori represents the basis for
treatment of gastric or duodenal peptic ulcers in
infected patients [11 16 17 23 24]. It seems in all
likelihood to be sufficient to heal duodenal and gas-
tric ulcers [25-30]. The anti-infectious treatment can
be combined with antisecretory symptomatic treat-
ment [25 30].
Finally, various studies present the eradication
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Abstract
The eradication of Helicobacter pylori is at present widely
recognized as the adequate therapeutic approach for gastric
and duodenal ulcers in infected patients. In those with
dyspepsia but no ulcer as well as in those with type B chronic
gastritis, eradication remains controversial.
It is difficult to have a clear opinion on the advantages and
disadvantages of the numerous existing therapies. Therefore,
a systematic review of published treatments has been made
by the authors. Ideally, the eradication treatment of H. pylori
should have the following advantages: 1. eradication
superior to 90%, 2. simplicity, 3. short duration, 4. safety, 5.
low cost, 6. reproducibility of results.
Dual therapies (2 antibiotics or a proton pump inhibitor in
combination with an antibiotic) rarely allow an eradication
greater than 90% and the results have poor reproductibility.
Consequently, they do not represent an ideal anti-H. pylori
treatment.
Triple therapies come closer to the requirements for an ideal
treatment, with eradication rates generally close to 90%,
varying little between studies and the countries in which they
were performed. The triple therapy bismuth-imidazole-
tetracycline (or amoxicillin) still represents for many authors
the standard reference therapy. It has the advantage of low
cost, high efficacy and widespread use. It is the therapy that
has been the most studied. However, the increasing
emergence of strains resistant to imidazoles, the complexity
of the treatment (10 to 12 tablets per day), the numerous
adverse effects and the lack of availability of bismuth salts in
certain countries has led to the elaboration of therapeutic
schemes combining an antisecretory drug with 2 antibiotics.
Among these, the combination PPI-clarithromycine-imidazole
during 7 days represents the most studied triple therapy of
short duration. For some authors, it already represents a new
standard. However, the efficacy of this therapy seems
dependent on the sensitivity of the bacteria to imidazoles.
Consequently, this combination cannot be considered as the
ideal anti-H. pylori treatment in the areas where the
prevalence of strains resistant to imidazoles is high. The
association PPI-clarithromycine-amoxicillin appears on the
contrary to be very effective against strains resistant to
metronidazole and therefore could constitute the treatment
of choice in population with high prevalence of such strains.
Great hope is currently surrounding the finalization of a
vaccine directed against the urease of the bacteria. This
approach would allow both the treatment and the
prevention of Helicobacter pylori infection on a large scale.
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treatment of H. pylori as the most economical method
of controlling peptic ulcer [14 15 31], while others
clearly point to an improvement of the quality of life
for ulcer patients after the elimination of the bacteri-
um [31 32].
Indications for eradication treatment of
Helicobacter pylori
The wide prevalence of infection by this bacterium in
the general population makes it difficult to envisage,
with our present knowledge, antibiotic treatment of
all infected patients. The eradication of H. pylori is
consequently limited to a group of persons present-
ing the most serious symptomatology.
In 1994, a consensus conference was held in the
United States under the aegis of the National
Institutes of Health (NIH) in order to define the indica-
tions of the treatment of H. pylori infection [23].
The conclusions of this conference are supported
by numerous authors of review articles from various
countries around the world and by another consensus
conference held by the French National Society for
Gastroenterology [7 16 24 33-35].
Gastric or duodenal ulcers
At the end of the above-mentioned conference, the
consensus panel of experts estimated that a sufficient
amount of data existed to recommend eradication in
all patients presenting a gastric or duodenal ulcer
associated with H. pylori infection in the case of a first
occurrence, a recurrence or a peptic ulcer associated
with the taking of NSAIDs.
It was also recommended that patients benefitting
from a chronic gastric antisecretory treatment (H2-
receptor antagonist or proton pump inhibitor) for the
prevention of simple or complicated (hemorraghic)
ulcer recurrences should be treated as well, if they
were infected. At the same time, the maintenance of
preventive antisecretory treatment, along with the
eradication of H. pylori, remains, until proven other-
wise, necessary in cases involving prevention of seri-
ous complications of peptic ulcer disease.
Gastritis and dyspepsia without ulcerative lesions,
gastric cancers
The consensus panel of the conference held by the
NIH (1994) [23] estimated that it was not justified,
with our present knowledge, to treat a patient infect-
ed by H. pylori, presenting gastritis without ulcerative
lesions, with or without dyspepsia. It also concluded
that a relationship between the bacterium and the
development of a gastric cancer, having not been suf-
ficiently studied to date, a systematic eradication of
the micro-organism as a preventive measure could
not be recommended.
However, despite these recommendations and the
still uncertain and contradictory data on the cause-
effect relationship between infection by H. pylori and
non-ulcer dyspepsia [36], some specialists propose
eradication (around 50% of the dyspeptic patients are
infected) in cases where symptomatic treatments
(reputed as being effective) have failed. In some dys-
peptic patients the result of eradication is spectacular,
whilst in others it is without effect [33 37-39]. The
vast majority of studies that have examined the effect
of H. pylori eradication on symptoms in non-ulcer dys-
pepsia have only a short follow-up period, usually 1-3
months [36 38]. However, the physiologic anomalies
(hypergastrinaemia, hyperacidity, delayed gastric
emptying) take much longer to resolve [38 40].
Therefore it is important in such studies to have longer
observation periods. In recent studies in which
patients have been followed for 12 months, there was
a clear advantage of eradication [38 40].
As regards chronic gastritis of patients infected by
H. pylori without ulcerative lesions, the benefit that
eradication could bring is still widely debated. It is
presently admitted that chronic gastritis is a factor
predisposing to the development of cancer, as it can
evolve towards atrophy, metaplasia and dysplasia [41-
44]. H. pylori is recognized as the causal agent of
chronic active gastritis type B (70% to 90% of chronic
active gastritis) [36 45-47] thus, it represents one co-
factor of gastric carcinogenesis. Consequently, some
specialists propose an eradication treatment of the
bacterium in infected patients with gastritis and
severe symptoms or intense inflammatory reactions,
or in individuals from families with a history of cancer
and those in whom evidence of atrophy, metaplasia
or dysplasia are found early in life [33 35].
If it is true that a cause-effect relationship exists
between H. pylori and the gastric cancers (grade 1
carcinogens) [41-44 48 49], the value of eradication
with the goal of cancer prevention has still not been
scientifically proven in the general population and
among dyspeptics. The number of patients suscepti-
ble to developing an adenocarcinoma or a gastric
lymphoma is minimal in proportion to the population
infected.
Though the importance of eradication of H. pylori is
not yet clearly demonstrated in gastric adenocarcino-
ma, the importance of the elimination of this germ in
the control of gastric lymphoma of type low-grade
MALT (mucosa-associated lymphoma tissue) is, on
the other hand, becoming increasingly recognized. In
certain studies a recovery from the lymphoma after
eradication of the bacterium was obtained in more
than 2/3 of the cases [43 50 51 52].
In Ménétrier’s hypertrophic gastritis, it is admitted-
ly beneficial to eradicate the germ because of possible
regression of lesions known to be at high risk of can-
cers [53].
Eradication treatments of Helicobacter
pylori 
The present review was based on a MEDLINE search
of literature from 1988 to 1996 and on abstracts pre-
sented at gastroenterology meetings. Articles and
abstracts were reviewed regardless of study design.
For each evaluated therapy regime, only studies that
used optimal and comparable dosage and duration of
treatment were included in the compilation of the
combined eradication rates presented.
H. Pylori is a bacterium with a slow growth rate,
and its eradication generally necessitates polytherapy.
The antimicrobial drugs used for its elimination are
divided into two categories: those having topical
activity and those having systemic activity. In fact,
only the bismuth salts have an activity which is
uniquely topical. The antibiotics used for the treat-
ment all have activity which is both topical and
systemic.
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Ideally, the eradication treatment of H. pylori should
have the following features:
- efficacy (rate of eradication of the bacterium nearly
100%)
- simplicity (small daily doses and short duration of
treatment in order to obtain the best possible
adherence to the treatment)
- safety
- good tolerance
- low cost
It is important to differentiate between the clearance
and the eradication of H. pylori. The former corre-
sponds to the absence of evidence of the bacterium
at the end of a therapeutic period, which can be
obtained with the aid of any treatment acting on the
growth of the micro-organism. The eradication by
contrast implies the absence of evidence of the bacte-
rium at least four weeks after the end of the treat-
ment. This alone corresponds to a true cure of the
infection.
Single therapies
Despite high sensitivity of H. pylori to a large number
of antibiotics in vitro, the first therapeutic tests in vivo
using single-drug therapy were disappointing, the
rates of eradication obtained rarely surpassing 20 %
(Table 1).
Bismuth
Bismuth subcitrate and subsalicylate are the two salts
most often used for the treatment of H. pylori infec-
tions. They are not commercialized in all European
countries because of the possible risk of encephalopa-
thy observed during prolonged treatment in patients
presenting severe renal insufficiency, or during the
administration of other, more soluble, salts of bis-
muth. The systematic absorption rate of these two
salts being very low, side effects are extremely rare
[60]. Bismuth subnitrate is also used in some coun-
tries [30]. All these salts are topically ulcer-healing
drugs as effective as the H2-receptor antagonists; they
stimulate the synthesis of the gastric prostaglandins
and, in an acid environment, form a protective layer
covering the ulcer crater. Furthermore, they have an
antibacteriuml effect on H. pylori. They disturb the
integrity of the bacterium cell wall, the adhesion of
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Table 1 In vitro antibacterial activity and clinical efficacy of antimicrobial and anti-ulcer agents against
Helicobacter pylori infection [54-59]
Class Agent MIC90 [µg/ml] % Eradication
ß-Lactams Amoxicillin 0.02 0-30
Penicillin 0.03 0
Ampicillin 0.2 -
Cefaclor 1 -
Cefotaxime 1 -
Imipenem <2 -
Macrolides Clarithromycin 0.03 36-42
Erythromycin 0.25 5-7
Azithromycin 0.25 -
Tetracyclines Tetracycline 1.2 0
Doxycycline 2.4 0
Nitroimidazoles Metronidazole 1 5-30
Tinidazole 4 5
Others antibiotics Ciprofloxacin 0.25 0
Ofloxacin 1 0-5
Clindamycin 8 0-10
Furazolidone 2.4 0-44
Rifampicin 1 0
Sulfonamides >500 -
Vancomycin >500 -
Bismuth salts Bismuth subcitrate 5-25 0-30
Bismuth subsalicylate 5-25 0-30
Anti-ulcerants Cimetidine >500 0
Ranitidine >500 0
Sucralfate >500 -
Al(OH)3 >3200 -
Omeprazole 20-25 0-14
Lansoprazole 6 0-10
MIC90: concentration of drug (µg/ml) required to inhibit 90% of strains of Helicobacter pylori.
% Eradication: number of patients successfully treated / number of patients treated
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micro-organism to the gastric epithelium and enzy-
matic functions of the bacterium [61]. It is still not
known whether their ulcer-healing activity is due to
their antibacterium or cytoprotective properties.
In single therapy, the rates of eradication obtained
with these bismuth salts are low (20%), but they are
still useful when combined with two antibiotics in
triple therapy. These are the first antiulcer drugs to
have been studied in H. pylori infections. In fact, it was
long ago observed that recurrences one year after the
cure of a peptic ulcer were less frequent after treat-
ment with bismuth than after treatment using a H2-
receptor antagonist [62 63].
Dosages used: subcitrate of bismuth : 480 mg/d;
subsalicylate of bismuth: 1200-1800 mg/d.
Amoxicillin
Even though H. pylori is very sensitive in vitro to
Amoxicillin, the rates of eradication obtained in single
therapy are around 20%. This antibiotic represents
one of the basic molecules for the eradication treat-
ment of the bacterium, by reason of the absence of
resistance observed up to now and its strong secre-
tion at the gastric level [55 64]. Even though this
penicillin is relatively stable in an acid environment, it
reaches its maximum activity at a pH of near neutral-
ity, which explains the important increase of activity
in combination with a gastric antisecretory drug [65]
(Table 3). 
Dosage used: 1500-2000 mg/d.
Tetracycline
In vitro, H. pylori is also very sensitive to tetracycline,
an antibiotic which, like amoxicillin, does not seem to
lead to resistance and with effectiveness little influ-
enced by gastric acidity [55]. A strain of H. pylori
resistant to tetracycline has however already been
described [66], contrary to amoxicillin. The low rates
of eradication obtained in vivo in single therapy, how-
ever, confines its use to triple therapy.
Dosages used: 1500-2000 mg/d.
Metronidazole
This molecule is highly active against H. pylori. It is
strongly secreted at the gastric level [67], and has lit-
tle sensitivity to gastric pH [55]. Its use however is
partially limited by frequent resistance of the bacteri-
um to this antibiotic (Table 2). Its combination with a
salt of bismuth and another antibiotic increases its
efficacy [68]. Tinidazole has properties equivalent to
those of metronidazole.
Dosage used: 1000-1500 mg/d.
Macrolides and azilide
These antibiotics are very effective in vitro on H. pylori,
the MIC90 situated between 0.03-0.25 µg/ml. In vivo,
only azithromycine and roxithromycine in a limited
number of studies [70-75] and especially clarithromy-
cine have shown an interesting activity in dual and
triple therapy. The poor results obtained with the
other macrolides seem principally related to their
instability in acid environments [76].
Clarithromycine has shown excellent results, main-
ly in dual and triple therapy, but also in single therapy
with 36-42% eradication of the bacterium, which for
single therapy is exceptional. Despite its high cost
and the emergence of resistances (1-12% in devel-
oped countries) [69 77-85], it represents, at present,
one of the basic molecules for the eradication treat-
ment of H. pylori.
Dosage used: 500-1500 mg/d.
Other antibiotics
In spite of a strong activity in vitro, quinolones, clin-
damycin and rifampicin have not shown sufficient
efficacy in vivo for use in H. pylori infections.
Ulcer-healing drugs
The antacids appear less active in vitro (MIC90 40 to
>3200 µg/ml) and in vivo against H. pylori, despite
the partially contradictory results reported by some
studies [56 86-88].
H2-receptor antagonists seem inactive in vitro and
in vivo [87 88] against the bacterium, but they main-
tain an important place in eradication treatment
because in raising the gastric pH, they potentiate the
activity of certain antibiotics.
According to research, the observed activity of
sucralfate against the bacterium is quite variable [89
90]. However, one recent study has demonstrated that
sucralfate can potentiate the action of different antibio-
tics (amoxicillin, tetracycline, metronidazole and eryth-
romycine) against H. pylori, as effectively as omeprazole
[91]. Furthermore, a recent review of reports found an
average eradication rate of 80% for triple therapy com-
bining sucralfate with two antibiotics [92]. But the
position of sucralfate remains to be clarified.
The proton pump inhibitors (PPIs) have a known
activity in vitro and in vivo against H. pylori, with
MIC90 close to those of bismuth salts and imidazoles
with which these molecules have certain structural
similarities [54]. In vivo, the rates of eradication
obtained with omeprazole and lansoprazole in single
therapy according to studies vary between 0% and
14% [57 58]. The importance that these molecules
have in the eradication treatment of H. pylori is related
to their strong capacity for raising the gastric pH, thus
allowing potentiation of the effects of certain antibio-
tics [57 58 65]. 
Table 2 Prevalence rates of metronidazole resis-
tance in various countries [68 69]
Countries Prevalence
Spain 6%
Sweden 10%
Ireland 7-20%
Portugal 23%
Italy 23%
Netherlands 6-41%
France 25%
United Kingdom 19-33%
Belgium 24-29%
Switzerland 30%
Finland 27-36%
Greece 45%
Australia 17%
Canada 35%
Zaire 84%
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5Table 3 Dual therapy regimens in the eradication of Helicobacter pylori
Drugs used Dosage Duration # Eradicated/# Treated
% Eradication Authors (references)
Bismuth: SCBC 480mg/d 14-42 days
or SSB 1800-2000mg/d 86/197
+ Amoxicillin 1500-2000mg/d 7-28 days 43.7%
(from 28 to 60%)
Bismuth: SCBC 480mg/d 7-28 days 65/118
or SSB 2080mg/d 55.1%
+ Metronidazole 1000-1500mg/d 7-14 days (from 38 to 79%)
Bismuth: SCBC 480mg/d 14 days 33/48
+ Clarithromycin 1000mg/d 14 days 68.8%
Metronidazole or 1200mg/d 7 days 98/170
Tinidazole 1000-2000mg/d 4-8 days 57.6%
+ Amoxicillin 1500-2000mg/d 4-8 days (from 52 to 69%)
Amoxicillin 2000-3000mg/d 14 days
671/1015
+ Omeprazole 40-80mg/d 14 days 66.1%
or (from 28 to 92%)
Lansoprazole 60mg/d 14 days
Clarithromycin 1000-1500mg/d 14 days
401/545
+ Omeprazole 40-80mg/d 14 days 73.6%
or (from 55 to 83%)
Lansoprazole 60mg/d 14 days
SCBC = bismuth subcitrate colloidal
SSB = bismuth subsalycilate
# Treated = cumulated number of patients treated in the reviewed clinical studies
# Eradicated = cumulated number of patients successfully treated in the reviewed clinical studies
% Eradicated = overall eradication rate
Chiba (1992) [59]
Chiba (1992) [59]
Noach (1994) [57]
Rauws (1992) [96]
Chiba (1992) [59]
Adamek (1992) [97]
Labenz (1992) [98]
Logan (1992) [99] 
Wagner (1992) [100]
Labenz (1993) [93]
Rokkas (1993) [101]
Atherton (1994) [102]
Goh (1994) [103]
Labenz (1994) [104]
Labenz (1994) [105]
Labenz (1994) [106]
Logan (1994) [107]
Tyszkiewicz (1994) [108]
Al-Assi (1995) [109]
Cayla (1995) [110]
Graham (1995) [111]
Jaspersen (1995) [20]
Jaspersen (1995) [21]
Laine (1995) [112]
Parente (1995) [113]
Saberi-F (1995) [114]
Soulé (1995) [115]
Meining (1996) [116]
Sung (1996) [27]
Vanderhulst (1996) [117]
Burette (1993) [118]
Neri (1993) [119]
Greaves (1994) [120]
Gurbuz (1994) [121]
Logan (1994) [107]
Logan (1994) [122] 
Neri (1994) [123] 
Harris (1995) [124] 
Hunt (1995) [125] 
Katelaris (1995) [126] 
Logan (1995) [127] 
O’Morain (1995) [128] 
Takimoto (1995) [129]
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Dual therapy
Different treatments combining a bismuth salt and an
antibiotic, two antibiotics, or an antisecretory drug
and an antibiotic, have been tested with the aim of
improving rates of eradication obtained in single ther-
apy or of diminishing the side-effects associated with
bismuth-metronidazole-tetracycline triple therapy
[93] (Table 3).
Only the antisecretory/antibiotic combination has
given good results with rates of eradication capable of
surpassing 80%. The two most-studied dual therapies
are those combining a proton pump inhibitor (PPI)
and amoxicillin or clarithromycin.
Some researchers have studied the H2-receptor
antagonist/clarithromycin and H2-receptor antago-
nist/amoxicillin combinations with a high dose of an
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Table 4 Triple therapy regimens in the eradication of Helicobacter pylori
Drugs used Dosage Duration # Eradicated/# treated
% Eradication Authors (references)
Bismuth: SCBC 480mg/d
or SSB 1000-2000mg/d 14 days 491/563
+ 87.2%
Tetracycline 1250-2000mg/d 14 days (from 65 to 94%)
+ 
Metronidazole 800-1200mg/d 14 days
Bismuth: SCBC 480mg/d
or SSB 1000-2000mg/d 7 days 338/404
+ 83.7%
Tetracycline 1500-2000mg/d 7 days (from 65 to 94%)
+ 
Metronidazole 800-1200mg/d 7 days
Bismuth: SCBC 480mg/d 
or SSB 1000-2000mg/d 14 days 223/261
+ 85.4%
Amoxicillin 1500-3000mg/d 14 days (from 81 to 100%)
+ 
Metronidazole 800-1500mg/d 14 days
Bismuth: SCBC 480mg/d
or SSB 1000-2000mg/d 7-14 days 121/162
+ 74.7%
Amoxicillin 1500-3000mg/d 7 days (from 50 to 90%)
+ 
Metronidazole 800-1500mg/d 7 days
Ranitidine 300-600mg/d 35-42 days
+ 79/93
Clarithromycin 400-500mg/d 7-14 days
+ 84.9%
Metronidazole or 500-1000mg/d 7-14 days (from 78 to 93%)
Tinidazole
Ranitidine 300mg/d 42 days
+ 25/29
Clarithromycin 1500mg/d 10 days
+ 86.2%
Amoxicillin 2250mg/d 10 days
Ranitidine 300mg/d 42 days
+ 114/137
Amoxicillin 1500-2250mg/d 12-15 days
+ 83.2%
Metronidazole or 1000-1500mg/d 10-14 days (from 75 to 89%)
Tinidazole
Rodionoff (1990) [134]
Bell (1992) [135]
Daskalopoul. (1992) [136]
Graham (1992) [137]
Labenz (1992) [138]
Sobala (1992) [139]
Balatsos (1993) [140]
Culter (1993) [141]
Thijs (1993) [142]
Iser (1994) [143]
Rodionoff (1990) [134]
Daskalopoul. (1992) [136]
Hosking (19940 [25]
Noach (1994) [57]
De Boer (1995) [144]
Phull (1995) [145]
Sung (1995) [26]
Sung (1996) [27]
Börsch (1989) [146]
Rautelin (1992) [147]
Seppala (1992) [148]
Tucci (1994) [149]
Chen (1995) [150]
Börsch (1989) [146]
Lambert (1990) [151]
Rauws (1990) [152]
Lambert (1994) [153]
Chen (1995) [150]
Kihira (1996) [156] 
Spadaccini (1996) [157]
Yousfi (1996) [158]
Al-Assi (1994) [159]
Lamouliatte (1992) [160]
Hentschel (1993) [11]
Powell (1994) [161]
Lahaie (1995) [162]
Phar vol 20_1  21-01-1998 15:55  Pagina 6
antisecretory drug (1200 mg ranitidine). The rates of
eradication were close to those obtained with a PPI
(84% for the ranitidine/clarithromycin combination
and 69% for the ranitidine/amoxicillin combination)
but they have not been confirmed [94 95].
PPI-amoxicillin
In spite of the very promising results of the first stud-
ies citing eradication rates of greater than 80% [97
98 100], the efficacy of this therapy seems to vary
considerably (28% to 92% eradication of H. pylori)
depending on the study and the place in which it was
performed, with no clear explanation of the differenc-
es. In studies done in Germany, eradication rates near
80% were observed [20 21 93 97 98 104-106],
while studies made in other countries (USA, France,
Italy, Great Britain, etc.) frequently showed rates of
elimination less than 60% [99 109-115]. This thera-
peutic schema, however, is the only one to have
exhibited an efficacy through intravenous methods
[64]. In 1993, Axon (VIth Workshop on Gastroduo-
denal Pathology and Helicobacter pylori. Brussels,
1993) defined the optimal conditions for use of this
dual therapy based on a review of articles on 14 stud-
ies (essentially German). According to the author, it is
the therapy using omeprazole 2 x 20 mg/d (or lan-
soprazole 2 x 30 mg/d) and amoxicillin 2 x 1000
mg/d for 14 days which allows the best rates of eradi-
cation to be obtained. Though the duration of the
treatment and the daily doses of the PPI and the anti-
biotic are also considered optimal by other authors,
the division of the doses of the PPI (2 x 20 mg of
omeprazole/d as opposed to 1 x 40 mg/d) by con-
trast is not unanimously considered to be a determin-
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Table 4 Continued
Drugs used Dosage Duration # Eradicated/# treated
% Eradication Authors (references)
IPP:    Omeprazole 20-40mg/d
or    Lansoprazole 30-60mg/d 7 days 895/990
or    Pantoprazole 80mg/d
+ 90.4%
Clarithromycin 500mg/d 7 days (from 69 to 96%)
+ 
Metronidazole  800-1000mg/d 7 days
or    Tinidazole
IPP:    Omeprazole 40-80mg/d
or    Lansoprazole 60mg/d 7 days 239/254
+ 
Amoxicillin 2000mg/d 7 days 94.1%
+ 
Clarithromycin 1000mg/d 7 days (from 77 to 98%)
IPP:    Omeprazole 40mg/d 
or    Lansoprazole 60mg/d 7 days 273/317
+ 
Amoxicillin 2000mg/d 7 days 86.1%
+ 
Clarithromycin 500mg/d 7 days (from 77 to 98%)
IPP:    Omeprazole 40mg/d 
or    Lansoprazole 30-60mg/d 7 days 434/539
+ 
Amoxicillin 1500-2000mg/d 7 days 80.5%
+ 
Metronidazole 800-1200mg/d 7 days (from 73 to 91%)
or Tinidazole
SCBC = bismuth subcitrate colloidal
SSB = bismuth subsalycilate
# Treated = cumulated number of patients treated in the reviewed clinical studies
# Eradicated = cumulated number of patients successfully treated in the reviewed clinical studies
% Eradicated = overall eradication rate
Bazzoli (1994) [164]
Moayyedi (1994) [165]
Moayyedi (1994) [166]
Jaup (1995) [167]
Buckley (1995) [168] 
Grasso (1995) [169]
Jaup (1995) [170]
Labenz (1995) [171]
Labenz (1995) [172]
Labenz (1995) [173]
Lind (1995) [174]
Deltenre (1996) [175]
Misiewicz (1996) [176]
Peitz (1996) [77]
Pryce (1996) [81]
Sito (1996) [177]
Lind (1995) [174]
Schütze (1995) [179]
Laine (1996) [180]
Monès (1996) [181]
Peitz (1996) [182]
Lind (1995) [174]
Labenz (1996) [183]
Misiewicz (1996) [176]
Yousfi (1996) [184]
Lind (1995) [174]
Bell (1995) [185]
Labenz (1996) [183]
Misiewicz (1996) [176]
Sito (1996) [177]
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Table 5 One, two and four day treatments
Drugs used Dosage Duration # Eradicated/# treated
% Eradication Authors (references)
Bismuth: SCBC 4 x 240mg 1 day
+ 
Amoxicillin 4 x 2000mg 1 day 23/32 Tucci (1993) [187]
+ 71.8%
Metronidazole 4 x 500mg 1 day
+ 
Omeprazole 1 x 40mg 1 day
Bismuth: SCBC 4 x 300mg 1 day
+ 
Amoxicillin 4 x 2000mg 1 day 19/26 Dobrucali (1993) [188]
+ 73.1%
Metronidazole 4 x 500mg 1 day
+ 
Omeprazole 1 x 40mg 1 day
Bismuth: SCBC 4 x 240mg 1 day
+ 
Amoxicillin/acid clav. 4 x 500/250mg 1 day 18/23 Takats (1994) [189]
+ 78.3%
Metronidazole 4 x 500mg 1 day
+ 
Omeprazole 1 x 20mg/d 28 days
(1st day: 40mg)
Bismuth: SCBC 4 x 240mg/d 1 day
+ Wermeille (1998) [193]
Amoxicillin 4 x 2000mg/d 1 day 3/15 Cunningham [193]
+ 20%
Clarithromycin 4 x 500mg/d 1 day
+ 
Lansoprazole 3 x 30mg/d 1 day
Bismuth: SCBC 4 x 240mg/d 2 days
+ 
Amoxicillin 4 x 1000mg/d 2 days 27/30 Tucci (1995) [190]
+ 90.0% (*)
Tinidazole 4 x 500mg/d 2 days
+ 
Omeprazole 1 x 40mg/d 7 days
Bismuth: SCBC 4 x 240mg/d 2 days
+ 
Tetracycline 4 x 500mg/d 2 days 20/26 Kung (1996) [191]
+ 76.9%
Metronidazole 4 x 400mg/d 2 days
+ 
Omeprazole 2 x 20mg/d 7 days
Bismuth: SCBC 4 x 120mg/d 4 days
+ 
Tetracycline 4 x 500mg/d 4 days 49/54 De Boer (1995) [192]
+ 90.7%
Metronidazole 3 x 500mg/d 4 days
+ 
Omeprazole 2 x 20mg/d 7 days
SCBC = bismuth subcitrate colloidal
SSB = bismuth subsalycilate
# Treated = cumulated number of patients treated in the reviewed clinical studies
# Eradicated = cumulated number of patients successfully treated in the reviewed clinical studies
% Eradicated = overall eradication rate
(*) : In this study, one inclusion criterion was: ‘susceptibility of the isolated strains of H. pylori to both amoxicillin and tinidazole’.
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ing element [101 107 111 130 131]. 
Dosages and duration of this therapy are summar-
ized in Table 3.
PPI-clarithromycin
Numerous studies of this combination have been
made showing eradication rates varying between
55% and 83%, in which omeprazole and clarithromy-
cin were administered at doses equal to or higher
than 40 mg and 1000 mg per day, respectively, for 14
days (Table 3). The reasons for this dispersion of
results in different studies remains unexplained. The
emergence of H. pylori strains resistant to clarithromy-
cin could be a possible explanation. It is presently
established that the doses of omeprazole and of cla-
rithromycin proposed below correspond to the mini-
mum necessary for obtaining a good response with
this dual therapy [132]:
Dosages and duration of this therapy are summar-
ized in Table 3.
Triple therapies
Triple drug therapy constitute presently the most cer-
tain means of obtaining an efficacy equal or superior
to 90%. Furthermore, they seem to have the advan-
tage that they can be administered for a shorter dura-
tion (7 days), when compared to dual therapy, with a
superior rate of eradication (Table 4).
Bismuth-tetracycline (or amoxicillin)-metronidazole
This treatment is internationally recognized, notably
by the consensus specialists of the conference held in
1994, under the aegis of the National Institutes of
Health (NIH) [23] and by a group of experts which
met during the 1990 world Congress of gastroente-
rology in Sydney.
This is the first combination to allow a rate of eradi-
cation higher than 90%. The results obtained by
Borody et al. (94% eradication) [133] with this type of
treatment were later confirmed by numerous other
studies carried out in different countries, where met-
ronidazole was sometimes replaced by tinidazole and
tetracycline by amoxicillin. The combinations with
the latter antibiotic seem nevertheless to be slightly
less effective [57] (Table 4). Thousands of patients
throughout the world have been treated with the aid
of these triple therapies, that have the advantage of
high efficacy and low cost. Disadvantages comprise,
on one hand, frequent adverse effects (observed in
20% to 60% of patients), in general in the digestive
tract, and on the other hand the large number of tab-
lets (10 to 12 per day) patients have to take. These
are two important factors compromising therapeutic
compliance. Further, a diminution of efficacy of the
combinations is observed in patients carrying strains
resistant to imidazoles (6% to 45% of strains resistant
to metronidazole in Europe) (Table 2). Though these
triple therapies are in general very effective (eradica-
tion rate greater than 90%) for patients carrying
strains sensitive to imidazoles, they allow an eradica-
tion of the bacterium in only 30% to 70% of patients
infected by a strain resistant to this family of antibio-
tics [135 139 147 154]. The usual duration of these
triple therapies (and the most studied) is 14 to 15
days, but it seems that a treatment of 7 days has com-
parable efficacy [34 57 59 134 136 150 155]
(Table 4). Strictly concerning eradication of the bacte-
rium with bismuth-tetracycline-metronidazole therapy,
the benefit of adding a gastric antisecretory (H2-
receptor antagonist or PPI) remains highly disputed
and differs depending on the study [25 30 144
145]. However, some benefit can be expected for the
symptomatic treatment of peptic ulcers.
For this review, we only take into consideration
triple therapies without addition of an antisecretory
agent. The most of the published studies on Bismuth
triple therapies use a H2-receptor antagonist, and are
consequently quadruple therapies.
Dosages and duration of this therapy are summar-
ized in Table 4.
H2-receptor antagonist-2 antibiotics 
This type of combination has shown good results in
some studies, with eradication rates between 78%
and 93%, depending on the particular combination
used [11 156-162] (Table 4).
H2-receptor antagonist being inactive against H.
pylori (MIC>500), the results obtained with these
therapies suggest that the inhibition of acid secretion
plays a predominant role in the efficacy of treatments
combining a gastric antisecretory and 2 antibiotics,
compared to the direct effect on the bacterium that is
observed with the proton pump inhibitors.
Dosages and duration of this therapy are summar-
ized in Table 4.
Proton pump inhibitors (PPI)-2 antibiotics
This type of triple therapy has acquired a wide popu-
larity by reason of its high efficacy (eradication rates
generally superior to 90%), its low number of adverse
effects and its short duration of treatment (7 days),
which facilitates compliance, an important factor in
success of the treatment [163].
PPI-clarithromycin-imidazoles
It was Bazzoli et al. who first proposed in 1993 a short
triple therapy with reduced doses combining 20
mg/d of omeprazole, 2 x 250 mg/d of clarithromycin
and 2 x 500 mg/d of tinidazole for 36 patients, with
100% elimination of the infection [163]. This result
has since been supported by a number of other stud-
ies [77 81 164-168 170 171 173 174 176 177]
which have further demonstrated that substitution of
tinidazole by metronidazole did not influence efficacy.
Efficacy does seem however to diminish in cases of
resistance of the bacterium to one of the two antibio-
tics [78 80 81]. The eradication of H. pylori appears
similar if the antisecretory is used in single doses (20
mg/d of omeprazole or 30 mg/d of lansoprazole) or
double doses [166]. The administration of clarithrom-
ycin in small doses (250 mg/d) offers the double
advantage of a diminution of the frequency of the
adverse effects and of the cost of the treatment. This
combination currently represents, for some authors, a
standard to which new therapies should be compared
[191].
Dosages and duration of this therapy are summar-
ized in Table 4.
PPI-clarithromycin-amoxicillin
This combination also allows excellent results to be
obtained (in general > 90% eradication), particularly
in studies where clarithromycin was administered in
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doses of 2 x 500 mg/d [174 179-182]. It offers an
interesting alternative of short triple therapy in coun-
tries where the resistance to imidazoles is high. The
use of clarithromycin in doses of 2 x 500 mg/d seems
more effective than its administration in weaker doses
(2 x 250 mg/d), but this remains to be verified [174]
(Tables 4). This type of treatment represents the most
onerous 7-day triple therapy. The impact of resistance
of H. pylori to clarithromycin on the efficacy of the
treatment is not well documented, by reason of the
infrequency of strains resistant to macrolides.
Presently the optimal dose of the PPI is not clearly
defined. A daily dose of 20 mg omeprazole or of 30
mg lansoprazole is probably sufficient, but the studies
carried out to date almost all used a double dose of
antisecretory.
Dosages and duration of this therapy are summar-
ized in Table 4.
PPI-amoxicillin-metronidazole
This combination seems somewhat less effective than
the two preceding combinations [34 174 176]
(Table 4), but it represents an interesting alternative
in cases of resistance or of contraindication of the cla-
rithromycin.
Dosages and duration of this therapy are summar-
ized in Table 4.
Two vast multicentric tests have been carried out in
order to make a comparison between the different 7-
day triple therapies combining a PPI and two antibio-
tics. The largest of these, the MACH 1 study [174],
was carried out on 787 patients (of which 684 could
be evaluated) in 5 countries (Germany, Canada,
Ireland, the United Kingdom and Sweden). It allowed
the comparison of 5 different combinations. The sec-
ond study [176], more recent, was carried out on 496
patients (of which 465 could be evaluated) in 4 cen-
ters of the United Kingdom. It allowed the compari-
son of 4 different combinations. These two multicen-
tric studies have confirmed the high efficacy of the
triple therapies PPI-clarithromycin-amoxicillin and PPI-
clarithromycin-metronidazole.
Other therapies and experimental therapies
Triple therapies comprising sucralfate or a zinc salt and
two antibiotics
As cited above, a recent review of articles has found
an average eradication rate of 80% (59% to 100%
depending on the study) with the combination
sucrasulfate + 2 antibiotics [92]. 
A triple therapy combining a zinc salt, metronida-
zole and amoxicillin has shown an efficacy of 100% in
a study carried out on 26 patients [186].
These two substances thus appear promising, but
their place in the eradication treatment of  H. pylori
still remains to be confirmed by other studies.
Treatments of 1, 2 and 4 days
The search for a treatment of very short duration with
the goal of improving compliance to reduce treat-
ment failure has led some researchers to experiment
with quadruple therapies (bismuth-PPI-amoxicillin (or
tetracycline)-imidazole) of 1, 2 and 4 days duration
with eradication rates that are quite acceptable (72,
73 and 77% for treatment of one day, 77 and 90%
for treatments of 2 days and 91% for a treatment of 4
days)[187-192] (Table 5). These results, obtained
with a relatively moderate number of patients, still
require confirmation. But these treatments appear to
be very promising, particularly in geriatrics where
compliance is often very poor for reasons of the poly-
pharmacy which applies principally to that age
group. However, the authors of this review have eva-
luted in a randomized clinical study the efficacy of a
‘one-day-quadruple-therapy’ containing amoxicillin,
clarithromycin, bismuth subcitrate and lansoprazole
(Table 5). An eradication rate of only 20% was
obtained. It was interesting to note that 90% of the
patients who failed with the ‘one-day-quadruple-ther-
apy’ were healed of their infection after 7 days of
triple therapy consisting of amoxicillin, clarithromycin
and lansoprazole [193].
Ranitidine bismuth citrate
The efficacy of this molecule (combination of two
antiulcer drugs) in healing the infection of H. Pylori
and of peptic ulcers has been demonstrated in several
studies. The eradication rates obtained with this
molecule are low and correspond to those observed
with only bismuth (0-20%). By contrast, in combina-
tion with an antibiotic, the rates of elimination of the
bacterium vary between 48% and 94% depending
on the dose administered and the antibiotic used
[194-199]. The best results (82-94% eradication)
have been obtained with 800 mg/d of ranitidine-bis-
muth-citrate for 4 weeks combined with 1000-1500
mg/d of clarithromycin for 14 days [194-197]. This
treatment appears to be well tolerated and very effec-
tive, but the results, obtained with a relatively moder-
ate number of patients (17-58 persons per group of
patients treated), requires confirmation. The principal
disadvantage of this dual therapy is its duration (4
weeks).
Eradication treatment of H. pylori by topical administra-
tion of anti-infectious agents
A topical treatment of one hour has shown an efficacy
of 96% in a study carried out on 25 patients [200].
The patients were pretreated for two days with the
aid of lansoprazole and pronase, before receiving, by
means of a nasogastric probe directly in the stomach,
a solution containing subnitrate of bismuth, amoxicil-
lin, metronidazole and pronase. The solution was
removed by aspiration one hour after its introduction.
Vaccine
The large prevalence of the H. pylori infection in the
general population and the  inherent difficulties with
its elimination by antibiotics has lead to the develop-
ment of a vaccinal approach and to the search for
vaccine with preventative and therapeutic properties.
Various teams are currently working to finalize a vac-
cine against bacterial urease. The results obtained in
animal experiments [201 202] and in the first clinical
test on humans allows hope for a vaccine against H.
pylori to be on the market within the next years.
Control of the efficacy of the treatment and
reinfection
The success of the eradication treatment of H. pylori is
defined arbitrarily as the absence of evidence of the
bacterium at least 4 weeks after the end of the thera-
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py [203]. The evaluation of the efficacy of a treatment
is made ideally with the Carbon-13 Breath Urea Test,
which is reliable and non invasive (specificity and sen-
sitivity superior to 90%) [204]. This test relies on the
enzymatic hydrolysis of ingested urea (labeled with
carbon-13 (13C), a stable isotope) by urease, an
enzyme present in high concentration in H. pylori
infection. Urea labeled with 13C is ingested by the
patient and hydrolysed in the stomach by the urease
of the bacterium into ammonia (NH3) and carbon
dioxide (13CO2). The 
13CO2 passes into the blood and
is eliminated by the lungs into the air expired where
the proportion of 13CO2 is measured. 
Culture, which requires endoscopic biopsy, none-
theless remains the method of reference.
Because today’s treatments have a high efficacy
(rate of eradication close to 90%), as a general rule,
verification of the elimination of the bacterium is not
performed except in cases of complicated, refractory
and relapsing ulcers.
In developed countries, the rate of reinfection is
understood to be between 0.5 and 1% per year [205
206].
Adverse effects
Adverse effects appear in 10% to 60% of patients
depending on the treatment used. They consist most
frequently of minor incidents (nausea, loose stool,
diarrhea, changes in taste, dizziness, headaches),
which rarely necessitate cessation of treatment (2 to
5% depending of the treatment studied).
The dual therapy PPI-amoxicillin seems to be the
treatment that presents the lowest amount of adverse
effects (0-20% depending on the study), while the
triple therapies Bismuth-biantibiotics (comprising
more than 1000 mg/d of metronidazole), may be the
ones that present the most (20-60% depending on
the study) [154]. In a recent review of articles,
Penston [207] found an average frequency of side
effects of 11% (n = 84/737) for the dual therapy PPI-
amoxicillin. The same author reported 32% of adverse
effects (n = 474/1492), for triple therapy combining
bismuth and 2 antibiotics. The side effects requiring a
cessation of treatment were 2% for dual therapy and
4% for triple therapy. These results are supported by
various reviews and studies which directly compared
these 2 treatments in the same group of patients [27
93] and by the studies cited in Tables 3 and 4.
The dual therapy PPI-clarithromycin shows
(depending on the study) 20-50% adverse effects, of
which the most frequent is a metallic taste, directly
related to the doses of clarithromycin administered.
During the 7-day triple therapies combining a PPI
and 2 antibiotics, one generally observes 15 to 30%
undesirable effects. In the majority of cases these
comprise diarrhea, most frequent in cases where
amoxicillin is used, or alteration of taste, most fre-
quent in patients consuming 2 x 500 mg/d of clarith-
romycin. The short-duration-triple-therapy proposed
by Bazzoli et al. (PPI + 2 x 250mg of clarithromycin +
2 x 500 mg of tinidazole or metronidazole) [164]
appears to be the best tolerated [131 174 208]
(studies cited in Tables 3 and 4).
Factors contributing to the failure of treat-
ments
Bacterium resistance to antibiotics
This represents a major factor in the failure of a treat-
ment. Among the antibiotics used for the elimination
of this bacterium, only amoxicillin and tetracycline do
not appear to induce resistant strains. To date, resis-
tance to amoxicillin has never been recorded, and
very rarely to tetracycline [66]. Resistance concerns
principally the imidazoles (metronidazole and tinida-
zole) with rates of 6-45% in Europe [68]. The resis-
tance of H. pylori to the macrolides is less well docu-
mented, because of its low prevalence. It seems more
common in France and Belgium (5-12% of resistant
strains) [79 83-85], compared to other industrialized
countries, where the primary rate of resistance is gen-
erally less than 5% [69 77 80-82].
It appears that the development of the resistance
to nitroimidazoles and to macrolides is strongly relat-
ed to their prior use in the treatment of other infec-
tions (parasitic, gynecological, lung or ORL infections)
and the therapeutic failures after dual or triple thera-
py [78-80]. The largest prevalence of resistant strains
is observed in countries where these antibiotics are
the most widely used. Metronidazole is frequently
used in Zaïre for different parasitoses. In this country,
there is a rate of resistance to imidazoles greater than
80% [68]. In France and Belgium, where macrolides
are frequently used as a primary intention for various
benign infectious ailments (ORL), the rate of resis-
tance varies between 5 and 10%.
With regard to the standard triple therapies com-
bining bismuth, tetracycline (or amoxicillin) and met-
ronidazole, the impact of the resistance of H. pylori to
imidazoles is relatively well documented. In general
an eradication rate above 90% is found in patients
carrying strains sensitive to metronidazole, and 30 to
70% in cases of resistant strains [135 139 147 154].
The influence of the sensitivity of strains to imida-
zole and to macrolides on the eradication rates
obtained with triple therapies of short duration com-
bining a PPI and 2 antibiotics is very poorly docu-
mented. Nevertheless it seems that the combination
PPI-clarithromycin-imidazole is very effective only on
strains sensitive to both the antibiotics (eradication
rate near 100%). In cases of resistance to imidazoles,
the eradication rate drops to 52-88% and to 0% in
cases of resistance to 2 antibiotics [77-81 166]. The
rate of eradication obtained with the triple therapy
PPI-amoxicillin-clarithromycin and the triple therapy
PPI-amoxicillin-metronidazole also appears to lower
in cases of resistance to clarithromycin for the former
and to imidazoles for the latter [161 209-211]. The
results obtained to date with the combination PPI-
amoxicillin-clarithromycine on the strains resistant to
metronidazole are excellent (eradication rates on the
order of 90%) [211-213].
Therapeutic compliance
For some authors, this represents the most important
factor in determining success of the treatment [214].
It depends on factors which are subjective (personal-
ity of the patient, symptom of the illness, etc.) as well
as objective, such as the number of daily dosages, the
appearance of adverse effects, the duration and the
complexity of the treatment. With triple therapy com-
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bining bismuth, tetracycline and metronidazole,
Graham et al. have observed an eradication rate of
69% in the group of patients having taken less than
60% of the prescibed drugs and an eradication rate of
96% in the group of patients having taken more than
60% of the treatment [137]. Similar results have been
observed for the dual therapy omeprazole-amoxicillin
and the triple therapy omeprazole-amoxicillin-metro-
nidazole [102 141 215 216].
Other factors
The activity of certain antibiotics on H. pylori strongly
depends on pH. This is the case notably for amoxicil-
lin and the macrolides (in a small way for clarithromy-
cin, azithromycin and roxithromycin), which exert
their maximum activity at a neutral pH. Only the
imidazoles, the tetracyclines and the bismuth salts are
not affected by gastric acidity. This may explain the
low efficacy of the triple therapy bismuth-amoxicillin-
metronidazole compared to the triple therapy bis-
muth-tetracycline-metronidazole. Similarly a low gas-
tric pH over the course of the therapy PPI-amoxicillin
could explain partly the failures observed with this
treatment [214].
The consumption of tobacco appears to diminish
the efficacy of certain eradication treatments of H.
pylori. It seems to have no effect on the dual therapy
PPI-clarithromycin, but could diminish the eradication
rates obtained with the dual therapy PPI-amoxicillin
and the triple therapy PPI-clarithromycin-metronida-
zole [214 217 218].
Discussion and conclusion
Eradication is at present clearly indicated in H. pylori
gastric and duodenal ulcers. In patients with dyspep-
sia but no ulcer as well as in those with type B chronic
gastritis, eradication remains controversial and is not
widely accepted in these settings.
It is difficult to have a clear opinion on the advan-
tages and disadvantages of the numerous therapies
cited in this article, as there are presently no large
studies which compare the efficacy, adverse effects,
compliance and the eradication rates obtained  in
relation to sensitivity to antibiotics of the different
treatments. According to Axon [219] and Lamouliatte
[209], the criteria for an ideal eradication treatment of
H. pylori are the following: 1. eradication superior to
90%, 2. simplicity, 3. short duration, 4. safety, 5. low
cost, 6. reproductibility of results.
Dual therapies rarely allow an eradication rate
greater than 90% (Table 3: 64% on the average for
the combination PPI-amoxicillin, 74% for the combi-
nation PPI-clarithromycin), and the results have poor
reproductibility (eradication rates varying between 28
and 92% for the combination PPI-amoxicillin, and
between 55 and 84% for the combination PPI-clarith-
romycine). Consequently, they do not represent an
ideal anti-H. pylori treatment, despite the good toler-
ance of the PPI-amoxicillin therapy.
Triple therapies come closer than the dual therapies
to the requirements for an ideal treatment of the
infection, with eradication rates generally close to
90%, varying little between the studies and the coun-
tries in which they were performed. The triple therapy
bismuth-imidazole-tetracycline (or amoxicillin) still rep-
resents for many authors the standard reference treat-
ment [23 154 220]. It has the advantage of low
cost, high efficacy and widespread use. It is therapy
that has been the most studied and documented.
However, the increasing emergence of strains resist-
ant to imidazoles, the complexity of the treatment
(10 to 12 tablets per day), the frequency of adverse
effects and the lack of availability of bismuth salts in
certain countries has led to the elaboration of thera-
peutic schemes combining an antisecretory drug with
2 antibiotics. Among these, the combination PPI-cla-
rithromycine (2 x 250 mg/d)-imidazole (2 x 500
mg/d) represents the most studied triple therapy of
short duration. It is very effective (eradication rates
superior to 90%), requires relatively few dosages (5 to
6 per day), is of short duration (7 days) and seems to
be better tolerated than other triple therapies. For
some authors, it already represents a new standard
[178]. However, the efficacy of this therapy seems to
be dependent on the sensitivity of the bacterium to
imidazoles. Consequently, this combination cannot
be considered as the ideal anti-H. pylori treatment in
the areas where there is a high prevalence of strains
resistant to imidazoles. The association PPI-clarithrom-
ycin-amoxicillin appears on the contrary to be very
effective against strains resistant to metronidazole
[211-213], and could therefore constitute the treat-
ment of choice in populations with high prevalence of
such strains.
Clarithromycin has numerous interactions with dif-
ferent drugs metabolized by cytochrome P450 (cisa-
pride, terfenadine, astemizole, theophylline, carba-
mazepine). The triple therapy standard (bismuth-
biantibiotics) and the combination PPI-amoxicillin-
metronidazole are consequently of particular interest
for patients requiring doses of one of these medicines.
The efficacy of therapies combining an H2-receptor
antagonist and 2 antibiotics is presently well demon-
strated. However, studies are still too few and the data
allowing a comparison of these treatments with those
comprising a PPI are still insufficient and disputed
[156 157 160-162 221]. A comparative study car-
ried out on a large collective of patients will be neces-
sary for determining the place of the H2-receptor
antagonist in the treatment of H. pylori.
The treatments based on sucralfate, zinc sulfate,
ranitidine bismuth citrate, the topical treatments, and
the therapies of very short duration (1-2 days), could
all present certain advantages, but an insufficient
number of studies is available.
Great hope is currently surrounding the finalization
of a vaccine directed against the urease of the bacteri-
um. This approach would simultaneously allow both
the treatment and the prevention of H. pylori infection
on a large scale.
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